Ivabradine hydrochloride
[CAS# 148849-67-6]

Identification

• Classification: Biochemical >> Inhibitor >> Neuronal signaling >> Adrenergic receptor inhibitor
• Name: Ivabradine hydrochloride
• Synonyms: 3-[3-[[(8S)-3,4-Dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one hydrochloride
• Molecular Formula: C₂₇H₃₆N₂O₅.HCl
• Molecular Weight: 505.05
• CAS Registry Number: 148849-67-6
• EC Number: 638-798-3
• SMILES: CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.Cl

Properties

• Solubility: 82 mg/mL (water), 100 mg/mL (DMSO) (Expl.)

Safety Data

• Hazard Symbols: GHS07;GHS08;GHS09 Danger
• Risk Statements: H302-H360-H373-H400
• Safety Statements: P203-P260-P264-P270-P273-P280-P301+P317-P318-P319-P330-P391-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400
Reproductive toxicity	Repr.	1B	H360
Acute toxicity	Acute Tox.	4	H302
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Chronic hazardous to the aquatic environment	Aquatic Chronic	2	H411
Reproductive toxicity	Lact.	-	H362
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413
Chronic hazardous to the aquatic environment	Aquatic Chronic	1	H410
Eye irritation	Eye Irrit.	2	H319

Discovery and Applications

Ivabradine hydrochloride is a pharmacologically active compound used primarily in the treatment of cardiovascular diseases, particularly in managing chronic heart failure and angina pectoris. It is a selective inhibitor of the If (funny) current in the sinoatrial node, the heart's natural pacemaker, and is marketed under the brand name Corlanor. The discovery and development of Ivabradine as a therapeutic agent stem from efforts to find treatments that specifically target heart rate regulation without negatively affecting other aspects of cardiac function.

The discovery of Ivabradine was a significant step forward in the field of cardiology, as it allowed for a more targeted approach to managing heart rate. By inhibiting the If current, Ivabradine slows down the heart rate without reducing the contractility of the heart, which differentiates it from other beta-blockers used in similar contexts. This selective mechanism of action makes Ivabradine an attractive alternative for patients who may not tolerate the side effects of traditional beta-blockers, such as fatigue or bronchospasm.

Ivabradine hydrochloride is commonly prescribed for patients with chronic heart failure, as it has been shown to improve symptoms by reducing the heart's workload and improving exercise capacity. It is also used in patients with stable angina pectoris, where it helps to reduce the frequency and severity of chest pain by lowering the heart rate and thereby decreasing myocardial oxygen demand. The compound is particularly useful in cases where beta-blockers are contraindicated or ineffective.

In addition to its role in managing heart conditions, Ivabradine has been studied for its potential in other areas, such as reducing the risk of arrhythmias and protecting against ischemic damage during heart attacks. It is often used in combination with other cardiovascular drugs to provide a comprehensive approach to managing heart disease. Its efficacy and safety profile have been demonstrated in numerous clinical trials, which have established it as a well-tolerated and effective option for patients with specific heart conditions.

Given its selective action on the If current, Ivabradine's pharmacological properties have sparked interest in the development of similar agents targeting other ion channels involved in heart rhythm regulation. This has opened up avenues for the design of novel therapies for a variety of cardiac disorders. Ongoing research continues to explore Ivabradine’s potential benefits in treating other conditions where heart rate modulation may play a critical role.

In conclusion, Ivabradine hydrochloride has become an important therapeutic agent in the treatment of heart failure and angina pectoris, offering a unique approach to managing heart rate and improving patient outcomes. Its selective action and favorable side effect profile make it a valuable option in cardiovascular medicine.

References

2021. Ivabradine induces cardiac protection against myocardial infarction by preventing cyclophosphamide-induced cardiac damage in a mouse model. Revista Española de Cardiología, 74(12).
DOI: 10.1016/j.rec.2020.09.012

2020. Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Heart Failure Reviews, 26(5).
DOI: 10.1007/s10741-020-10029-0

2019. pH-responsive smart gels of block copolymer [pluronic F127-co-poly(acrylic acid)] for controlled delivery of Ivabradine hydrochloride: its toxicological evaluation. Journal of Polymer Research, 26(8).
DOI: 10.1007/s10965-019-1872-8